OTLK — Outlook Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-06-14.
Performance
Technicals
Others in Healthcare
Measured signals that fired on OTLK
| date | signal | measured base rate |
|---|---|---|
| 2026-08-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-17 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-09 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-17 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-27 | Cluster buy: three or more insiders insider | +0.63% over 21 days · t = 1.84 · n = 3,050 not distinguishable from its control group |
| 2026-05-26 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-14 | KENYON LAWRENCE A Chief Financial Officer | Open-market purchase | 101.0K | — | — |
| 2026-08-14 | Jahr Robert Charles Chief Executive Officer | Open-market purchase | 151.5K | — | — |
| 2026-08-12 | GMS Ventures & Investments Director | Open-market purchase | 2.5M | 0.99 | 2.5M |
| 2026-08-12 | Sukhtian Ghiath M. Director | Open-market purchase | 2.5M | 0.99 | 2.5M |
| 2026-07-29 | Sukhtian Faisal Ghiath Director | Open-market purchase | 95.4K | 1.05 | 100.0K |
| 2026-06-02 | Haddadin Yezan Munther Director | Open-market purchase | 29.0K | 0.83 | 24.1K |
| 2026-05-28 | Sukhtian Ghiath M. Director | Open-market purchase | 8.5M | 0.59 | 5.0M |
| 2026-05-28 | GMS Ventures & Investments Director | Open-market purchase | 8.5M | 0.59 | 5.0M |
| 2026-05-27 | Sukhtian Faisal Ghiath Director | Open-market purchase | 122.2K | 0.41 | 50.0K |
| 2026-05-26 | HILZINGER KURT J Director | Open-market purchase | 400.0K | 0.44 | 176.5K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| ARMISTICE CAPITAL, LLC | 857.8K | 4.2M |
| VANGUARD CAPITAL MANAGEMENT LLC | 405.2K | 2.0M |
| GEODE CAPITAL MANAGEMENT, LLC | 124.2K | 603.6K |
| GILPIN WEALTH MANAGEMENT, LLC | 123.5K | 600.2K |
| BlackRock, Inc. | 98.3K | 477.5K |
| COMMONWEALTH EQUITY SERVICES, LLC | 96.7K | 470.0K |
| Warberg Asset Management LLC | 56.4K | 275.0K |
| RENAISSANCE TECHNOLOGIES LLC | 52.5K | 255.2K |
| NINE MASTS CAPITAL Ltd | 47.9K | 232.5K |
| Connective Capital Management, LLC | 41.2K | 200.0K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 10-Q | 2026-08-18 | 2026-06-30 | on EDGAR ↗ |
| NT 10-Q | 2026-08-17 | 2026-06-30 | on EDGAR ↗ |
| 4 | 2026-08-14 | 2026-08-14 | on EDGAR ↗ |
| SCHEDULE 13D/A | 2026-08-14 | — | on EDGAR ↗ |
| 4 | 2026-08-14 | 2026-08-12 | on EDGAR ↗ |
| 4 | 2026-08-14 | 2026-08-14 | on EDGAR ↗ |
| 8-K | 2026-08-14 | 2026-08-12 | on EDGAR ↗ |
| 424B5 | 2026-08-14 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Outlook Therapeutics, Inc. (OTLK) filed form 10-Q · 2026-08-18 · SEC EDGAR
- 5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In · 2026-08-17 · benzinga
- Outlook Therapeutics, Inc. (OTLK) filed form NT 10-Q · 2026-08-17 · SEC EDGAR
- Outlook Therapeutics targets more than $500M peak annual LYTENAVA sales by 2030 as it forecasts $50M-$75M first-year net revenue · 2026-08-14
- Outlook Therapeutics, Inc. (OTLK) filed form 8-K · 2026-08-14 · SEC EDGAR
- Outlook Therapeutics, Inc. (OTLK) filed form 8-K · 2026-08-14 · SEC EDGAR
Ask the AI about OTLK
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →